Literature DB >> 7492087

Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.

A Kitamura1, K Hoshino, Y Kimura, I Hayakawa, K Sato.   

Abstract

Inhibitory effects of five quinolones against DNA gyrases purified from four quinolone-resistant clinical isolates of Pseudomonas aeruginosa and the quinolone-susceptible strain PAO1 were examined. All of the quinolone-resistant strains tested were found to be DNA gyrase mutants. The 50% inhibitory concentrations (IC50s) of the quinolones for these DNA gyrases roughly correlated with their MICs. Interestingly, gyrase inhibition by DU-6859a was found to be significantly less affected by these mutations that inhibition by other currently available quinolones. To assess the enhanced activity shown by DU-6859a, the effects of quinolones with altered substituents at the N-1, C-7, and C-8 positions of the quinolone ring of DU-6859a were tested. Measurement of MICs for four DNA gyrase mutants and IC50s for their purified DNA gyrases showed that removal of the C-8 chlorine of DU-6859a significantly increased MICs and IC50s for DNA gyrase mutants. However, no deleterious effects were observed when either the fluorine on the cyclopropyl substituent at the N-1 position or the cyclopropyl ring at the C-7 substituent was removed. Moreover, removal of the C-8 chlorine also increased the MIC for 19 of 20 quinolone-resistant clinical isolates. Our results led to the conclusion that DU-6859a is much more active against quinolone-resistant clinical isolates of P. aeruginosa than other currently available quinolones, probably because of its strong inhibitory effects against mutant quinolone-resistant DNA gyrases, and that the C-8 chlorine is necessary for these potent effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492087      PMCID: PMC162764          DOI: 10.1128/AAC.39.7.1467

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa.

Authors:  L J Piddock; M C Hall; F Bellido; M Bains; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

2.  DNA gyrase: an enzyme that introduces superhelical turns into DNA.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; H A Nash
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

3.  Interaction between DNA and an Escherichia coli protein omega.

Authors:  J C Wang
Journal:  J Mol Biol       Date:  1971-02-14       Impact factor: 5.469

4.  Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition.

Authors:  K Hoshino; A Kitamura; I Morrissey; K Sato; J Kato; H Ikeda
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

5.  Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

Authors:  J Fung-Tomc; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

6.  Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.

Authors:  L Ferrero; B Cameron; B Manse; D Lagneaux; J Crouzet; A Famechon; F Blanche
Journal:  Mol Microbiol       Date:  1994-08       Impact factor: 3.501

7.  Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa.

Authors:  T Yoshida; T Muratani; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.

Authors:  K Sato; K Hoshino; M Tanaka; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

9.  (Fluorocyclopropyl)quinolones. 2. Synthesis and Stereochemical structure-activity relationships of chiral 7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-fluorocyclopropyl)quinolone antibacterial agents.

Authors:  Y Kimura; S Atarashi; K Kawakami; K Sato; I Hayakawa
Journal:  J Med Chem       Date:  1994-09-30       Impact factor: 7.446

10.  Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates.

Authors:  A Kureishi; J M Diver; B Beckthold; T Schollaardt; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

View more
  24 in total

1.  Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

Authors:  Xinying Li; Xilin Zhao; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining region.

Authors:  S M Friedman; T Lu; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae.

Authors:  F J Schmitz; M Boos; S Mayer; D Hafner; H Jagusch; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

4.  Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.

Authors:  Masaya Takei; Hideyuki Fukuda; Ryuta Kishii; Youko Kadowaki; Yukiko Atobe; Masaki Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

5.  Combinatorially-generated library of 6-fluoroquinolone analogs as potential novel antitubercular agents: a chemometric and molecular modeling assessment.

Authors:  Nikola Minovski; Andrej Perdih; Tom Solmajer
Journal:  J Mol Model       Date:  2011-08-12       Impact factor: 1.810

6.  Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones.

Authors:  X Zhao; J Y Wang; C Xu; Y Dong; J Zhou; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

7.  Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Pseudomonas aeruginosa bofilms displaying rapid-transport characteristics.

Authors:  J D Vrany; P S Stewart; P A Suci
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 8.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

9.  Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development.

Authors:  Tatsuo Yamamoto; Tomomi Takano; Wataru Higuchi; Akihito Nishiyama; Ikue Taneike; Kumi Yoshida; Hiroko Kanda; Yuichiro Imamura
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

10.  Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance.

Authors:  Y Dong; C Xu; X Zhao; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.